论文部分内容阅读
作者发现,一种新的蒽环类抗菌素Requinomycin具有抑制大肠杆菌菌株之间耐药因子(R-factor)的转移以及噬菌体f2对大肠杆菌感染的作用。Requinomycin的抑制作用必须在供体及受体细胞混合时加入以及在噬菌体感染时或感染前加入才有明显效果,若在后期加入requinomycin,则抑制作用极低或无抑制作用。Requinomycin并不直接影响噬菌体f2及大肠杆菌菌株,它不使耐药菌的耐药因子脱落。Requinomycin对大肠杆菌完整细胞无作用,但能显著抑制甲苯处理过的大肠杆菌细胞核糖核酸的合成,说明requinomycin不能渗透大肠杆菌细胞
The authors found that a new anthracycline Requinomycin inhibits the transfer of R-factors between E. coli strains and the effect of bacteriophage f2 on E. coli infection. The inhibition of requinomycin must be added when the donor and recipient cells are mixed together and added when the phage is infected or before infection. If requinomycin is added later, the inhibition is very low or not. Requinomycin does not directly affect bacteriophage f2 and E. coli strains, it does not cause the resistance factor of resistant bacteria to fall off. Requinomycin has no effect on E. coli whole cells, but it can significantly inhibit the synthesis of toluene-treated E. coli ribonucleic acid, indicating that requinomycin cannot penetrate E. coli cells.